{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:29Z","timestamp":1791918929447,"version":"4.3.4"},"reference-count":27,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse (N = 143). Next-generation sequencing (NGS) MRD detection &amp;gt;0 in bone marrow (BM) was highly associated with relapse. B-cell recovery [signifying loss of functional chimeric antigen receptor (CAR) T cells] within the first year of treatment was associated with a hazard ratio (HR) for relapse of 4.5 [95% confidence interval (CI), 2.03\u20139.97; P &amp;lt; 0.001]. Multivariate analysis at day 28 showed independent associations of BMNGS-MRD &amp;gt;0 (HR = 4.87; 95% CI, 2.18\u201310.8; P &amp;lt; 0.001) and B-cell recovery (HR = 3.33; 95% CI, 1.44\u20137.69; P = 0.005) with relapse. By 3 months, the BMNGS-MRD HR increased to 12 (95% CI, 2.87\u201350; P &amp;lt; 0.001), whereas B-cell recovery was not independently predictive (HR = 1.27; 95% CI, 0.33\u20134.79; P = 0.7). Relapses occurring with persistence of B-cell aplasia were largely CD19\u2212 (23\/25: 88%). Detectable BMNGS-MRD reliably predicts risk with sufficient time to consider approaches to relapse prevention such as hematopoietic cell transplantation (HCT) or second CAR-T cell infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Detectable disease by BMNGS-MRD with or without B-cell aplasia is highly predictive of relapse after tisagenlecleucel therapy for ALL. Clonotypic rearrangements used to follow NGS-MRD did not change after loss of CD19 or lineage switch. High-risk patients identified by these biomarkers may benefit from HCT or investigational cell therapies.<\/jats:p>\n                    <jats:p>See related commentary by Ghorashian and Bartram, p. 2.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 1<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-21-0095","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T04:35:51Z","timestamp":1638333351000},"page":"66-81","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":203,"title":["Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia"],"prefix":"10.1158","volume":"3","author":[{"given":"Michael A.","family":"Pulsipher","sequence":"first","affiliation":[{"name":"1Section of Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Han","sequence":"additional","affiliation":[{"name":"2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"4Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-3138","authenticated-orcid":false,"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"4Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."},{"name":"5Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-343X","authenticated-orcid":false,"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia."},{"name":"7Aflac Cancer and Blood Disorders Center, Healthcare of Atlanta, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-1831","authenticated-orcid":false,"given":"Susana","family":"Rives","sequence":"additional","affiliation":[{"name":"8Pediatric Hematology, Hospital Sant Joan de D\u00e9u de Barcelona, Fundaci\u00f3 Sant Joan de D\u00e9u, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Boyer","sequence":"additional","affiliation":[{"name":"9Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-5670","authenticated-orcid":false,"given":"Hidefumi","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"10Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto City, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Yanik","sequence":"additional","affiliation":[{"name":"11Michigan Medicine Bone Marrow Transplant and Leukemia, C.S. Mott Children's Hospital, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Driscoll","sequence":"additional","affiliation":[{"name":"12Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Doug","family":"Myers","sequence":"additional","affiliation":[{"name":"13Pediatric Hematology and Oncology, Children's Mercy Hospital; University of Missouri\u2014Kansas City School of Medicine, Kansas City, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[{"name":"14Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine Hospital for Children and Adolescents University Hospital Frankfurt, Frankfurt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0120-6089","authenticated-orcid":false,"given":"Andre","family":"Baruchel","sequence":"additional","affiliation":[{"name":"15Pediatric Hemato-Immunology Department, H\u00f4pital Universitaire Robert Debr\u00e9 (APHP), Paris, France."},{"name":"16Universit\u00e9 de Paris et Institut de Recherche Saint-Louis (EA3518), Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-4501","authenticated-orcid":false,"given":"Jochen","family":"Buechner","sequence":"additional","affiliation":[{"name":"17Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Stefanski","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics, The University of Minnesota Medical School, Minneapolis, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Creton","family":"Kalfoglou","sequence":"additional","affiliation":[{"name":"2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Nguyen","sequence":"additional","affiliation":[{"name":"2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Waldron","sequence":"additional","affiliation":[{"name":"2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Thudium Mueller","sequence":"additional","affiliation":[{"name":"2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald J.","family":"Maier","sequence":"additional","affiliation":[{"name":"19Novartis Pharmaceuticals Corporation, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Kari","sequence":"additional","affiliation":[{"name":"19Novartis Pharmaceuticals Corporation, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."},{"name":"4Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"2025112416470603000_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2025112416470603000_bib2","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"2025112416470603000_bib3","article-title":"Emily Whitehead Foundation [homepage on the Internet]"},{"key":"2025112416470603000_bib4","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2025112416470603000_bib5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2025112416470603000_bib6","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112416470603000_bib7","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"2025112416470603000_bib8","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"2025112416470603000_bib9","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"2025112416470603000_bib10","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112416470603000_bib11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"2025112416470603000_bib12","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv"},{"key":"2025112416470603000_bib13","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"2025112416470603000_bib14","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"2025112416470603000_bib15","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"2025112416470603000_bib16","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"2025112416470603000_bib17","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025112416470603000_bib18","first-page":"1281","article-title":"Impact of humoral immunogenicity (anti-mCAR19 antibodies) on CTL019 cellular kinetics, efficacy, and safety","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"2025112416470603000_bib19","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"2025112416470603000_bib20","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1200\/JCO.2008.16.1117","article-title":"Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials","volume":"26","author":"Attarbaschi","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025112416470603000_bib21","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/bmt.2008.58","article-title":"Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials","volume":"41","author":"Schrauder","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2025112416470603000_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025112416470603000_bib23","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","article-title":"The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group\/Pediatric Blood and Marrow Transplant Consortium trial","volume":"123","author":"Pulsipher","year":"2014","journal-title":"Blood"},{"key":"2025112416470603000_bib24","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025112416470603000_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"2025112416470603000_bib26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"2025112416470603000_bib27","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/3\/1\/66\/3269482\/66.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/3\/1\/66\/3269482\/66.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:47:14Z","timestamp":1764020834000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/3\/1\/66\/675483\/Next-Generation-Sequencing-of-Minimal-Residual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,1]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0095","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.6550538.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550538","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544129.v1","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.741265451.793598774","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.741265451.793591188","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.22544129","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]}}}